HALO AP 2.5 Sneak Peek Webinar
16 April 2026 | Learn about the exciting new features in the 2.5 versions of HALO AP®!
HALO AP 2.5 Sneak Peek Webinar Read More »
HALO AP
HALO AP® is Now Rated in Best in KLAS®: Earning ‘A’ Grades in All Categories
Albuquerque, NM, February 12, 2026 – Indica Labs, the world’s leading provider of AI-powered digital pathology solutions, today announced recognition by KLAS for top customer-rated performance in the European digital pathology market.
HALO AP® is Now Rated in Best in KLAS®: Earning ‘A’ Grades in All Categories Read More »
Indica Labs Sets New Standard for Molecular Testing in Breast Cancer with Expansion of AI Macrodissection Portfolio
Albuquerque, NM, February 10, 2025 – Indica Labs, the world’s leading provider of AI-powered digital pathology solutions, today announced the expansion of its macrodissection portfolio with the launch of Breast Macrodissect AI . The suite now includes advanced algorithms for non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and breast cancer, with prostate cancer planned for release in early 2026.
Looking Back: Reviewing 2025 at Indica Labs
As we reach the end of 2025, the Indica Labs team extends our sincere thanks to the customers and collaborators who helped make this year one of remarkable innovation, growth, and scientific achievement.
Looking Back: Reviewing 2025 at Indica Labs Read More »
Indica Labs Reports 260% Clinical Revenue Growth and Expansion into New Global Markets
Albuquerque, NM, December 17, 2025 – Indica Labs, the global leader in AI-powered digital pathology, announced today that clinical revenue growth rate for HALO AP® is up 260% since 2023 and recurring revenue for 2025 shows a 200% increase year-over-year, reinforcing its position as a market leader in digital pathology diagnostics.
Indica Labs Reports 260% Clinical Revenue Growth and Expansion into New Global Markets Read More »
Indica Labs Receives FDA Clearance for Enterprise Digital Pathology Platform with Industry Leading DICOM-Compatible Aperio Scanner from Leica Biosystems
ALBUQUERQUE, NM, and VISTA, CA, December 3, 2025 – Indica Labs, the global leader of AI-powered digital pathology, and Leica Biosystems, a global leader in anatomic and digital pathology solutions, announced today that the Food and Drug Administration (FDA) has issued a 510(k) clearance for the enterprise digital pathology platform HALO AP Dx in conjunction with Leica Biosystems Aperio GT 450 DX Scanner for in-vitro diagnostic use.
HALO AP® and Breast IHC AI at MAPMG
Learn more about how MidAtlantic Permanente Medical Group (MAPMG) used Breast IHC AI deployed in HALO AP® to standardize prognostic scores in newly diagnosed breast cancers and increase diagnostic efficiency of first reads.
HALO AP® and Breast IHC AI at MAPMG Read More »
An Automated Clinical Workflow Integrating an AI-driven PD-L1 22C3 Scoring Algorithm into a Browser-Based Digital Pathology Solution
Discover how Guardant Health has seamlessly integrated Lunit SCOPE PD-L1 with HALO AP® for enhanced PD-L1 analysis.
People of Pathology Podcast: Adam Smith – Making AI Accessible For All With Indica Labs
Adam Smith shares his journey from being a HALO® customer to helping lead Indica Labs’ mission of making AI accessible to pathologists everywhere.
People of Pathology Podcast: Adam Smith – Making AI Accessible For All With Indica Labs Read More »